Versant Capital Management’s Ocular Therapeutix OCUL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.34K Buy
435
+76
+21% +$744 ﹤0.01% 2526
2026
Q2
$3.52K Buy
359
+129
+56% +$1.17K ﹤0.01% 2498
2026
Q1
$1.95K Sell
230
-17
-7% -$162 ﹤0.01% 2572
2025
Q4
$3K Buy
247
+17
+7% +$206 ﹤0.01% 2379
2025
Q3
$2.69K Hold
230
– – ﹤0.01% 2360
2025
Q2
$2.13K Hold
230
– – ﹤0.01% 2365
2025
Q1
$1.69K Hold
230
– – ﹤0.01% 2289
2024
Q4
$1.96K Hold
230
– – ﹤0.01% 2064
2024
Q3
$2K Buy
+230
New +$1.9K ﹤0.01% 1562

Other funds holding OCUL

Versant Capital Management's OCUL Position: Q3 2026 in Review

Versant Capital Management increased its Ocular Therapeutix (OCUL) stake by 21% in Q3 2026, buying an estimated $744 and bringing the position to 435 shares worth $3.34K. The position accounts for ﹤0.01% of the portfolio, ranked #2526.

Versant Capital Management first reported a position in OCUL in Q3 2024 and has held it in 9 quarters since. The position peaked at $3.52K in Q2 2026. 263 funds tracked by Wall St. Rank hold OCUL as of Q3 2026.

  • Versant Capital Management held 435 shares of Ocular Therapeutix worth $3.34K as of Q3 2026.
  • Versant Capital Management bought 76 Ocular Therapeutix shares in Q3 2026, an estimated $744.
  • Ocular Therapeutix made up ﹤0.01% of Versant Capital Management's portfolio in Q3 2026, its #2526 holding.
  • Versant Capital Management first reported a position in Ocular Therapeutix in Q3 2024 and has held it in 9 quarters since.
  • Versant Capital Management's Ocular Therapeutix position peaked at $3.52K in Q2 2026.
  • 263 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q3 2026.

Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.